Clinical Trials

29 enrolled

Liver Neoplasms

NCT07535632 2026-04-17

BEST

58 enrolled

Colorectal Neoplasms

NCT07537777 2026-04-17

Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy

29 enrolled

Carcinoma, Hepatocellular

NCT07537972 2026-04-17

Denosumab Strategy for Liver Cancer With Bone Metastases

50 enrolled

Carcinoma, Hepatocellular

NCT07530549 2026-04-15

A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy

40 enrolled

Esophageal Neoplasms

NCT07527520 2026-04-14

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial

165 enrolled

Rectal Neoplasms

NCT07527858 2026-04-14

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

170 enrolled

Advanced Microsatellite Stable Colorectal Cancer

NCT07529483 2026-04-14

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts

35 enrolled

Pancreatic Cystic Neoplasm

NCT06732388 2026-04-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

64 enrolled

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

44 enrolled

Rectal Cancer Patients

NCT07522476 2026-04-13

A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Carcinoma, Hepatocellular

NCT07514429 2026-04-07

RELEVANT-HCC

24 enrolled

Carcinoma, Hepatocellular

NCT07514455 2026-04-07

RECOMEND

20 enrolled

Carcinoma, Hepatocellular, Disease Progression

NCT07514533 2026-04-07

The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma

60 enrolled

Cholangiocarcinoma

NCT07515469 2026-04-07

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Carcinoma, Hepatocellular

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07515820 2026-04-07

SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study

12 enrolled

Colorectal Neoplasms

NCT07515963 2026-04-07

FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.

24 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT07516210 2026-04-07

ART-Hypo

GastrointestinalGenitourinaryGynecologic

264 enrolled

Uterine Cervical Neoplasms, Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

NCT07510932 2026-04-06

FIRST-K

88 enrolled

Colonic Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

40 enrolled

Carcinoma, Hepatocellular

NCT07511894 2026-04-06

BBNIGC

33 enrolled

Stomach Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT07507526 2026-04-02

DTP-HER2

76 enrolled

Gastric Adenocarcinoma

NCT07507916 2026-04-02

Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma

32 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07101666 2026-03-31

TNT-SHORT

20 enrolled

Stomach Neoplasms

NCT07503639 2026-03-31

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

134 enrolled

Locally Advanced Colorectal Cancer

NCT07503756 2026-03-31

JS212 Combination Therapies in Metastatic Colorectal Cancer

80 enrolled

Colorectal Neoplasms

NCT07502014 2026-03-30

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

60 enrolled

Colorectal Neoplasms

NCT07495579 2026-03-27

REVIVE

146 enrolled

Carcinoma, Hepatocellular

NCT04910386 2026-03-25

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

126 enrolled

Biliary Tract Neoplasms

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

CNSDermatologicGastrointestinal

260 enrolled

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT07493668 2026-03-25

FLEX-HCC

80 enrolled

Carcinoma, Hepatocellular

NCT07490002 2026-03-24

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

33 enrolled

Esophageal Squamous Carcinoma

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07486310 2026-03-20

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Advanced Gastric Cancer

NCT07483359 2026-03-19

CONV3RSION

38 enrolled

Carcinoma, Hepatocellular

NCT07483554 2026-03-19

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

389 enrolled

CLDN18.2 Positive

NCT06258525 2026-03-18

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Classical hematologyGastrointestinal

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

NCT07472933 2026-03-18

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

44 enrolled

Cancer of Biliary Duct

NCT07478523 2026-03-17

FAPDIG

120 enrolled

Cholangiocarcinoma

NCT07474727 2026-03-16

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

180 enrolled

Colorectal Neoplasms

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Locally Advanced Rectal Cancer

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Pancreatic Neoplasms

NCT07467590 2026-03-12

TRIUNITE-07

33 enrolled

Colorectal Neoplasms

NCT07381634 2026-03-11

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

134 enrolled

Carcinoma, Hepatocellular

NCT07463248 2026-03-11

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

64 enrolled

Carcinoma, Hepatocellular

NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

80 enrolled